

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the prospectus dated June 28, 2024 (the “**Prospectus**”) issued by Fangzhou Inc. (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia), or any jurisdiction where such release, publication or distribution is prohibited by law. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in Hong Kong, the United States or any other jurisdiction. The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or securities law of any state or other jurisdiction in the United States, and may not be offered, sold, pledged or otherwise transferred within the United States or to, or for the account or benefit of U.S. persons, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the securities in the United States. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

方舟健客

Fangzhou Inc.

方舟云康控股有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 6086)

STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on August 3, 2024, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Further information on the stabilizing actions undertaken by the Stabilizing Manager or any person acting for it during the stabilization period is set out in this announcement.

LAPSE OF OVER-ALLOTMENT OPTION

The Overall Coordinators (for themselves and on behalf of the International Underwriters) did not exercise the Over-allotment Option, which lapsed on August 3, 2024.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on August 3, 2024, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by the Stabilizing Manager or any person acting for it during the stabilization period are set out below:

- (a) over-allocation of an aggregate of 3,570,000 Shares in the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering;
- (b) borrowing of an aggregate of 3,570,000 Shares from Celaeno Group Limited pursuant to the Stock Borrowing Agreement to cover over-allocations in the International Offering; and
- (c) successive purchases of an aggregate of 3,570,000 Shares in the price range of HK\$4.41 to HK\$6.59 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565%) on the market during the stabilization period, representing approximately 15% of the Offer Shares initially available under the Global Offering. The last purchase made by the Stabilizing Manager or any person acting for it on the market during the stabilization period was on July 12, 2024 at the price of HK\$5.70 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565%).

LAPSE OF OVER-ALLOTMENT OPTION

The Overall Coordinators (for themselves and on behalf of the International Underwriters) did not exercise the Over-allotment Option, which lapsed on August 3, 2024. Accordingly, no Shares were or will be issued by the Company under the Over-allotment Option.

PUBLIC FLOAT

Immediately after the end of the stabilization period, the Company will continue to satisfy the minimum percentage of public float as prescribed in the waiver granted by the Stock Exchange from strict compliance with the requirement under Rule 8.08(1)(a) of the Listing Rules.

By order of the Board
Fangzhou Inc.
Mr. XIE Fangmin
Chairman

Hong Kong, August 4, 2024

As of the date of this announcement, the Board comprises Mr. XIE Fangmin, Mr. ZHOU Feng and Mr. ZOU Yuming as executive directors, Mr. David McKee HAND as non-executive director, and Dr. WANG Haizhong, Ms. KANG Wei and Mr. ZHU Xiaolu as independent non-executive directors.